Patents Represented by Attorney Jean M. Lahive & Cockfield Silveri
  • Patent number: 5629194
    Abstract: Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof).
    Type: Grant
    Filed: October 21, 1994
    Date of Patent: May 13, 1997
    Assignee: Diacrin, Inc.
    Inventor: Jonathan Dinsmore
  • Patent number: 5622705
    Abstract: The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recombinant poliovirus nucleic acid includes contacting a host cell with a recombinant poliovirus nucleic acid which lacks the nucleotide sequence encoding at least a portion of a protein necessary for encapsidation and an expression vector comprising a nucleic acid which encodes at least a portion of one protein necessary for encapsidation under conditions appropriate for introduction of the recombinant poliovirus nucleic acid and the expression vector into the host cell and obtaining a yield of encapsidated viruses which substantially comprises an encapsidated recombinant poliovirus nucleic acid.
    Type: Grant
    Filed: May 19, 1995
    Date of Patent: April 22, 1997
    Assignee: The UAB Research Foundation
    Inventor: Casey D. Morrow
  • Patent number: 5614413
    Abstract: The present invention pertains to a method of encapsidating a recombinant poliovirus nucleic acid to obtain a yield of encapsidated viruses which substantially comprises encapsidated recombinant poliovirus nucleic acid. The method of encapsidating a recombinant poliovirus nucleic acid includes contacting a host cell with a recombinant poliovirus nucleic acid which lacks the nucleotide sequence encoding at least a portion of a protein necessary for encapsidation and an expression vector comprising a nucleic acid which encodes at least a portion of one protein necessary for encapsidation under conditions appropriate for introduction of the recombinant poliovirus nucleic acid and the expression vector into the host cell and obtaining a yield of encapsidated viruses which substantially comprises an encapsidated recombinant poliovirus nucleic acid.
    Type: Grant
    Filed: January 22, 1996
    Date of Patent: March 25, 1997
    Assignee: The UAB Research Foundation
    Inventor: Casey D. Morrow
  • Patent number: 5593673
    Abstract: Isolated porcine pancreatic cells, isolated populations of such cells and methods for isolating and using the cells to treat subjects with diseases characterized by insufficient insulin activity are described. The porcine pancreatic cells are preferably non-insulin-secreting porcine pancreatic cell having the ability to differentiate into an insulin-secreting cell upon introduction into a xenogeneic subject, such as a human subject. Such cells include embryonic porcine pancreatic cells obtained from embryonic pigs between about day 31 and day 35 of gestation. The porcine pancreatic cells can be modified to be suitable for transplantation into a xenogeneic subject, for example, by altering an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in the subject (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof).
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: January 14, 1997
    Assignee: Diacrin, Inc.
    Inventor: Jonathan Dinsmore
  • Patent number: 5505723
    Abstract: Methods and apparatus as disclosed for shaping the cornea of a patient's eye such that the epithelial tissue of the patient's cornea is shaped into a preliminary shape, corresponding to a desired final stromal shape, using photoablative radiation, and then the preliminary shape of the epithelial tissue is transferred into the stromal tissue of the cornea using photoablative radiation, thereby shaping the cornea into the desired final stromal shape. The epithelium may be shaped using an erodible mask with a predefined profile of resistance to erosion, or by a graded intensity filter, or by selectively varying the dimension of an aperture that controls the area of the epithelial surface irradiated by the photoablative laser radiation or by other mechanisms that selectively expose regions of the epithelium, or by a scanning laser beam. The epithelium may also be shaped, without using an aperture or a mask, by using a beam of photoablative radiation with substantially uniform intensity distribution.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: April 9, 1996
    Assignee: Summit Technology, Inc.
    Inventor: David F. Muller